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Reduced expression ofTGFP is associated with advanced disease in
transitional cell carcinoma
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Summary The gene structure and expression of the related peptide regulatory factors TGFP1 and TGF,2
were studied in a panel of seven urothelial carcinoma cell lines and 40 transitional cell carcinomas. The latter
comprised 15 grade 1,18 grade 2 and 5 grade 3 tumours and two cases of carcinoma in situ. Control tissues
included ten matched 'field' biopsies and 17 other biopsies including 11 biopsies of macroscopically normal
urothelium, two of which were from patients with no history of bladder cancer. No amplification of
rearrangements of either TGFP1 or TGFP2 were detected in any sample. A complex pattern of expression or
the two genes was found in the urothelial cell lines. High, but variable levels of the 2.5 kb TGFP1 transcript
were detected and lower and more variable levels of the three (4.1 kb, 5.1 kb and 6.5 kb) transcripts ofTGFP2
were detected. Although those cell lines expressing most TGFPI tended to express less TGFl2 transcript there
was no clear-cut relationship. In comparison, no TGFP2 transcript was identified in any primary transitional
cell carcinoma or control tissue. Markedly reduced or undetectable levels ofTGFP1 transcript were detected in
4/15 (26%) grade 1, 5/18 (28%) grade 2 and 3/5 (60%) grade 3 tumours. There was no clear relationship to
tumour stage, lymphocytic infiltration or stromal content of the tumours. Clinical review one year after the 2
year period of tumour collection showed that 6/9 (66%) of patients with tumours with reduced levels of
transcript had died or had disease which was not controllable by local resection and 3/9 (33%) had developed
tumour re-occurrences. In comparison, in the group with normal levels of expression of TGFPi1, 3/18 (17%)
had disease which was not controllable by local means, 9/18 (50%) had tumour re-occurrence and 6/18 (33%)
had no evidence of disease. The association of reduced expression of TGF%1 and advanced disease was
statistically significant P<0.02 (Fisher's test). Although the sample size is small, we suggest that the loss of
expression of TGFP1 may be a potential marker of progressive disease or prognosis in transitional cell
carcinoma and warrants further study.
The TGFPI group of peptide regulatory factors is a large
expanding family of multi-functional genes displaying
marked homology and evolutionary conservation (Roberts &
Sporn, 1990). TGFP is secreted in a latent form which is
unable to bind to its receptor (Wakefield et al., 1987). Activa-
tion of this latent TGFP may be achieved in several ways
including transient acidification, alkalinisation or chaotropic
agents (Kryceve-Martinerie et al., 1985).
The action of TGFP is mediated through binding to
specific cell surface receptors. Almost all cells, regardless of
origin, bind TGFP (Roberts & Sporn, 1990). Three distinct
classes of receptor with various affinities for TGFP1 and
TGFPI2 have been described (Cheifetz et al., 1987) and it has
been suggested that the cell specific effects of the individual
forms of TGFP may be regulated by differences in the levels
of receptors of different affinities present on those cells
(Cheifetz et al., 1990).
The pleiotropic effects of the TGFPi family have been
extensively documented (for recent reviews see Moses et al.,
1990; Roberts & Sporn, 1990). The role of TGFPI in cell
transformation is unclear. Most normal epithelial cells in
tissue culture are growth inhibited by TGFP (Moses et al.,
1985; Masui et al., 1986; Jetten et al., 1986; Kurokowa et al.,
1987). In contrast many carcinoma cells show reduced inhibi-
tion by TGFPI (Wakefield et al., 1987; Lechner et al., 1983;
McMahon et al., 1986) and many transformed cell lines
secrete increased amounts of TGFPI (Derynck et al., 1987;
Jakowlew et al., 1988; Niitsu et al., 1988) which is reflected in
an increase in the steady-state levels of TGFPI mRNA in
these cell lines and in tumours. Such increased TGFPI produc-
tion could contribute to tumour development and progres-
sion in multiple ways via paracrine effects on neovascularisa-
tion, extracellular matrix formation, chemotaxis and
immunosuppression (Roberts et al., 1988). However, changes
in TGFP production and responsiveness are not demon-
strated in all transformed cells. Some remain growth
inhibited by TGF,B and not all transformed cells secrete
increased amounts ofTGFPi (Derynck et al., 1987; Wakefield
et al., 1987).
There have been few studies of TGFP production by
human tumours. Raised levels of TGFP mRNA were
reported in breast and renal tumours (Coombes et al., 1990;
Gomella et al., 1989). Similarly, TGFP1 RNA was detected
in all glial tumour cells in a spectrum of cerebral malignan-
cies (Mapstone et al., 1991). TGFP secretion and growth
response of urothelial cells has not been studied in detail.
The only report on bladder epithelial cells to date showed
that foetal urothelial cells but not transformed urothelial cells
responded to exogenous TGFP1 by a decrease in plasmino-
gen activator activity secondary to increased transcription of
PAI-I activity (Hiti et al., 1990).
Transitional cell carcinoma is the fourth most common
cancer in males in the United Kingdom and the incidence is
rising in both men and women (31% between 1971 and 1984,
OPCS, 1971-1984). Studies of the natural history of transi-
tional cell carcinoma have identified an aggressive subset of
tumours (Pryor, 1973). Identification of the molecular events
involved in the genesis of transitional cell carcinoma may
offer potential markers of disease progression and prognosis.
As part of a study aimed at identifying some of these lesions
in transitional cell carcinoma, we have examined the struc-
ture and expression of the genes encoding TGFPi1 and
TGFPi2 in human urothelial cancer cell lines and transitional
cell carcinomas.
We show that in bladder tumours, marked reduction or
loss of expression of the gene encoding TGFPI is associated
with advanced disease. No TGFP2 transcript could be
detected in these tumours. In urothelial cancer cell lines,
variable levels ofTGFPi1 and TGFP2 mRNA were expressed
with no apparent relationship between the relative amounts
of these transcripts.
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Materials and methods
Tissue samples
Tissue samples were collected from patients undergoing
cystoscopic examination at University College Hospital, the
Middlesex Hospital, the Shaftsbury Hospital and St Peters
Hospital, London. The tissue was cut with diathermy or
'cold' cup biopsy forceps and was removed from the bladder
as soon as possible, trimmed of debris and a representative
sample excised (including the base and attached normal tis-
sue) for histological assessment. Tumour size ranged from
60 mg to many grams but the majority (>80%) were small
and were processed as a single sample. Where biopsies of
normal urothelium or carcinoma in situ were taken, the
epithelial layer was dissected free of submucosa and muscle.
In these cases, urothelium from at least four biopsies from
the same patient was pooled and processed together. Tissues
were placed immediately at - 70°C. The tissues used are
shown in Table I. Tumours were graded according to
W.H.O. recommendations (1973) and staged using the TNM
system (UICC, 1978).
Cells and cell culture
The cell lines used were EJ (Evans et al., 1977), VM-CUB-2
(Williams, 1980), SCaBER (O'Toole et al., 1976), SD (Paulie
et al., 1983) and SW1710 (Kyriazis et al., 1984), J.O'N
(Human Tumour Cell Laboratory, Sloan Kettering Cancer
Center, personal communication) and 5637 (G. Gannon,
unpublished). All the cell lines were derived from transitional
cell carcinomas apart from SCaBER which was from a
squamous cell carcinoma of the bladder. EJ, VM-CUB-2 and
SCaBER were cultured in Dulbecco's modification of Eagle's
medium with 10% Newborn calf serum in an atmosphere of
10% CO2 in air. SD, JO'N, 5637 and SW1710 were cultured
in RPMI 1640 with 10% foetal calf serum in 5% CO2 in
air.
Isolation ofDNA and RNA
DNA and RNA were isolated from the same tumour sample
by the guanidine isothiocyanate method (Maniatis et al.,
1982). DNA was extracted twice with phenol, twice with
phenol:chloroform and once with chloroform, ethanol
precipitated and dissolved in 1 x TE prior to quantitation
and use. The RNA pellet was washed in 70% alcohol, air
dried and dissolved in 0.3 M sodium acetate pH 6.0 prior to
precipitation with two volumes of absolute ethanol and
storage at - 70'C.
Southern blotting
DNA samples were digested with EcoRI (Gibco BRL, Paisley,
Scotland) according to the manufacturer's instructions and
Table I Tissues used in the study
Transitional cell tumours:
TCC-Grade 1 15
TCC-Grade 2 18
TCC-Grade 3 5
CISa 2
Control tissues:
Matched field biopsies" 10
Unmatched field biopsiesc 3
Normal urotheliumd 11
Follicular cystitise 2
Post BCG cystitis 1
Nonnal lymphocytes I
aCarcinoma in situ; bBiopsies of urothelium with normal mor-
phology from tumour-bearing bladders; cBiopsies of urothelium from
tumour-bearing bladders for which no RNA was obtained from the
tumour; dNine biopsies obtained from bladders with no tumour at
check cystoscopy and two from patients undergoing prostatectomy;
eBoth biopsies were obtained at negative check cystoscopies.
the fragments separated in 0.8% agarose gels. Gels were
stained with ethidium bromide and photographed prior to
capillary transfer (Southern, 1975) onto Hybond-N mem-
branes (Amersham UK). Lambda DNA digested with Hind
III was used as size markers and lymphocyte DNA from
normal volunteers as a normal DNA control on each gel.
Blots were baked at 80°C for two hours and pre-hybridised
and hybridised following the manufacturer's instructions.
Following washing to high stringency (0.1% SSPE and 0.1%
SDS), blots were exposed to Hyperfilm-MP (Amersham UK)
at - 70°C with intensifying screens.
Northern blotting
Total cellular RNA was electrophoresed in 1% agarose/
formaldehyde gels (modified from Thomas, 1980) and trans-
ferred by capillary blotting to Hybond-N membranes. These
were pre-hybridised and probed according to the manufac-
turer's instructions. Some gels were stained with ethidium
bromide to compare loading and RNA inetegrity with the
results obtained from control probes. Blots were hyrbidised
sequentially to probes for TGFP1, TGFP2 and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). The 1.4 kb
GAPDH transcript migrated suitably close to the 2.5 kb
TGFI31 message to act as a good control for RNA loading
and degradation. Non-specific binding of the GAPDH probe
to the 28S ribosomal band was used as a control for TGFP2
(transcripts of 4.1 kb, 5.1 kb and 6.5 kb). In addition,
selected blots were hybridised to c-erbB-2 (transcript size
4.5 kb, not illustrated) to confirm the presence of intact RNA
in the size range of TGFP2. Levels of transcript in tumours
were compared with levels in control issues and scored as
normal (+), raised (+ +) or reduced or undetectable (0).
Blots were stripped by washing for two hours in 5 mM
Tris-HClpH 8.0, 2 mM Na2 EDTA and 0.1 x Denhardt's
solution at 650C.
Slot blotting
Slot blots were made on Hybond-N membranes using a
Schleicher and Schuell vacuum slot blotting apparatus. Each
slot received 2.5jig denatured total RNA. RNA was denatured
in 50% formamide, 5% formaldehyde, 1 x SSC at 680C for 15
min. Following application of the sample, the wells were
flushed with 100gl 20 x SSPE and the membranes baked at
800C. Hybridisation was as for Northern blots. Slot blots were
assessed by comparing the ratio of signals obtained with
GAPDH and the gene ofinterest for a reference slot containing
control tissue RNA with those obtained for tumour tissues.
Probes
The probes used were the 2.1 kb EcoRI fragment of
phTGFb-2 (TGFP1) cloned by Dr G. Bell and kindly sup-
plied with his permission by Dr J. Scott, the 2.3 kb EcoRI
fragment of pPC-21 (TGFi2, Madisen et al., 1988) supplied
by Oncogen Science (Manhasset, NY., USA) and the 1.3 kb
Pst-I fragment of pRGAPDH-13 (glyceraldehyde-3-phos-
phate dehydrogenase, Fort et al., 1985). Probes were labelled
by random priming (Feinberg & Vogelstein, 1983) and used
at 106 c.p.m. ml-' of hybridisation fluid.
Results
No structural alterations of the genes encoding TGFP1 or
TGF,B2 were detected by Southern blotting. Five fragments
at 22.8 kb, 15 kb, 5.2 kb, 2.1 kb and 1.75 kb were detected
with the probe for TGFP1 and four fragments at 17 kb,
10kb, 4.4 kb and 3 kb with the probe for TGFi2.580 L.M. COOMBS et al.
Expression ofTGFiI andTGFP2 RNA in urothelial
carcinoma cell lines
All seven bladder tumour cell lines examined expressed high
levels of TGFPIl mRNA of 2.5 kb (Figure la). SCaBER, a
cell line derived from a squamous cell carcinoma of the
bladder, showed the highest levels of expression and VM-
CUB-2 and JO'N the lowest levels. After allowance was
made for variations in loading and RNA degradation, 5637,
SW1710, EJ and SD were judged to express similar levels of
TGFP1I.
Levels ofTGFPI2 expression were more varied. The level of
expression of the three expected transcripts of 4.1 kb, 5.1 kb
and 6.5 kb differed within the same bladder tumour cell line
(Figure lb). Expression of the 5.1 kb and 6.5 kb transcripts
was greater than that of the 4.1 kb transcript. Total expres-
sion ofTGFP2 RNA also varied markedly between cell lines.
All cell lines expressed two of the three expected transcripts
of 6.5 kb and 5.1 kb respectively. VM-CUB-2 appeared to
express higher levels of the 6.5 kb than the 5.1 kb transcript
(Figure lb) but all other lines expressed more of the 5.1 kb
than the 6.5 kb transcript. This can be seen clearly for
SWI710 in Figure lb. The 4.1 kb transcript was only clearly
seen in VM-CUB-2. VM-CUB-2 expressed at least 10-fold
higher levels of TGFP2 than SWI710 which expressed the
second highest levels of TGFPI2 transcript. The failure to
detect the 4.1 kb transcript in these cell lines may reflect their
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Figure 1 Northern blot of urothelial carcinoma cell line RNA
hybridised sequentially to TGF,1, TGFP2 and GAPDH probes.
15 ;g total RNA was loaded in each track. a, Expression of
TGFP1 detected after high stringency washing and short exposure
of the autoradiograph. b, Expression of TGFP2 transcripts
(6.6 kb, 5.1 kb and 4.1 kb). After prolonged exposure. 6.5 kb and
5.1 kb transcripts could be detected in all cell lines. The 4.1 kb
transcript is visualised clearly only in VM-CUB-2. c, The 1.4 kb
transcript of GAPDH. Non-specific binding of the probe to the
28S ribosomal band was used as a control for RNA loading and
integrity.
lower total levels of TGFP2 expression. The cell line
SCaBER which expressed most TGFPI expressed the least
TGFPI2. However, there was no clear inverse relationship
between the expression of TGFPIl and TGF,B2 in the other
cell lines.
Expression ofTGFI3 andTGFl32 in primary transitional cell
carcinoma
Northern and slot blots of total RNA extracted from transi-
tional cell carcinomas were hybridised sequentially to
TGFP1, TGFP2 and GAPDH probes. RNA from 38 tumours,
two cases of CIS, ten matched and three unmatched field
biopsies, 11 normal urothelial biopsies, two biopsies of fol-
licular cystitis and one biopsy from a bladder with cystitis
following BCG treatment were analysed by Northern and
slot blots. Since large samples of normal urothelium from
individuals with no history of urological symptoms are not
available, samples of macroscopically normal urothelium
from several sources were assessed to provide a measure of
'normal' levels of expression. These included samples from
bladder tumour patients with no tumour at check cystoscopy
and from prostatectomy patients. Expression of TGFI in all
but one of these samples (see below) was similar and was
taken as the baseline level of expression. No aberrant trans-
cripts of TGFP1 were detected and the levels of transcript in
25 tumours were similar to those in normal urothelial con-
trols. In 12 tumours, reduced levels of transcript were
observed and in three tumours raised levels of transcript were
detected. Examples are shown in Figures 2 and 3. The char-
acteristics of these tumours are outlined and compared with
grade in Table II. Although the number of G3 tumours
analysed is small (five), the marked difference in the incidence
of tumours with reduced expression 3/5 (60%) suggests that
there is an association between high tumour grade and
reduced expression of TGFPI. No relationship between the
reduced levels of transcript of TGFPI and tumour stage or
the amount of stroma in the tumour biopsies was detected.
Three tumour re-occurrences (we have used this term for
subsequent tumours or 'recurrences' in the same patient,
since the relationship between initial and subsequent tumours
is unclear) were subsequently analysed. In two of these, the
level of expression of TGFPI was the same as that detected
in the initial sample. In the third, expression was reduced in
the initial biopsy and normal in the second.
Of the ten matched field biopsies, four showed similar
levels of expression of TGFP to the tumour from the same
bladder. These were comparable to levels detected in normal
urothelium. In three cases, transcript levels were reduced in
the tumour and not the field biopsy. In one patient, levels
were reduced in the field biopsy but not the tumour, in one
patient levels were reduced in both field and tumour biopsies
and in one patient transcript levels were raised in the tumour
but normal in the field biopsy. Of the three unmatched field
biopsies, one showed raised levels of transcript. In addition,
two biopsies of follicular cystitis (both from patients in
whom transitional cell carcinomas had been resected in the
past) were assessed. One of these showed reduced levels of
transcript. Only one of the samples of macroscopically 'nor-
mal' urothelium showed altered levels of transcript. This
sample was obtained from a patient in whom no re-occur-
rences were detected at check cystoscopy. Two biopsies from
this patient were assessed. One of these showed normal levels
of TGFPI transcript and the other had raised levels.
No TGFP2 transcript was detected in any tumour despite
the presence of intact 28S RNA bands. Furthermore, hy-
bridisation to other probes of similar transcript size (e.g.
ERBB2, 4.5 kb, not illustrated) confirmed the presence of
intact, high molecular weight mRNA of the expected tran-
script size of TGFP2.
Patientfollow up
Follow up data from this group ofpatients over the two year
period of tissue collection and for one additional year hasTGFP EXPRESSION IN TCC 581
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Figure 2 Northern blot of transitional cell carcinoma RNA hybridised sequentially to TGFP1 and GAPDH. 15 tLg of total RNA
was loaded in each track. Track 11 contains RNA isolated from normal urothelium. Tumours 1, 3, 4, 5, 7, 8, 9 show marked
reduction of TGFPI transcript.
been assessed. At the time of initial biopsy, all patients had
tumours which were considered to be controllable by local
resection. Since complete follow-up is not yet available for
most of these patients, progression was assessed on the basis
of tumour spread beyond control by local resection. Re-
occurrences are not considered as indicative of disease pro-
03
0L
CD
m
LL
CD
12 -
13-
14-
15-
16-
17 -
18-
control-
19f-
Figure 3 Slot blot of transitional cell carcinoma RNA hy-
bridised sequentially to TGFPI and GAPDH. 2.5pg total RNA
was loaded in each well. Compared with control RNA (isolated
from normal urothelium), tumours 16 and 17 (>) show reduced
expression of TGFPI and tumours 12 and 14 (>>) show
elevated levels of TGFPI. 19f is a field biopsy.
Table II TGFPI expression and grade
Expression of TGFB
Grade + +a + 0 % with reduced expression
1 1 10 4 26
2 2 11 5 28
3 - 2 3 60
CIS 2 -
a+ +, increased TGFP RNA levels; +, normal levels; 0, reduced
levels. Normal level of expression was defined as that detected in
macroscopically normal urothelium derived from several sources (see
text).
gression as they frequently show no increase in grade or
stage. Results are shown in Table III. These exclude the two
patients with CIS, one of whom was treated with BCG and
one with cystectomy, and one patient with a transitional cell
tumour who was too ill for any therapy (all of whom ex-
pressed normal levels ofTGFI). Correlation between reduced
expression of TGFJIl and disease progression was found
P = 0.02 (Fisher's test).
Discussion
The members of the TGFPi family of peptide regulatory
factors have been shown to play important roles in the
control of growth and differentiation of normal cells. A
number of observations suggest that differences in production
of, or response to TGFPi may play a role in transformation.
Here we have shown that expression of TGF,B1 and TGFP2
vary considerably in both urothelial carcinoma cell lines and
tumours. Nevertheless, results indicate a correlation between
decreased expression in tumours and clinical behaviour.
Northern analyses of total RNA from human bladder
tumour cell lines showed the expected transcripts for TGFPI
and TGFPi2. The three TGFP2 transcripts may result from
differential splicing and/or polyadenylation events. The
4.1 kb and the 6.5 kb messages are considered the major
transcripts of TGFP2 and have been described most com-
monly in other cell lines (Madisen et al., 1988; Derynck et
al., 1988). However, we found that the 6.5 kb and 5.1 kb
transcripts were the most abundant in urothelial carcinoma
cell lines and the 4.1 kb transcript was only clearly demon-
strated in one cell line. Since this did not reflect mRNA
degradation, it is likely that the various transcripts identified
in the urothelial tumour cell lines are differentially expressed
messages.
TGF,1I mRNA was expressed at higher levels than TGFP2
and although those cell lines with the highest levels of
TGFPI transcript tended to have lower levels of TGFP2
transcript, there was no clear inverse relationship. Tissue and
species specific differential expression of TGFPI1 and TGFP2
has been reported (Seyedin et al., 1985; Cheifetz et al., 1987;
Assoian et al., 1983; Derynck et al., 1988; Wrann et al., 1987;
Ikeda et al., 1987). However, results obtained using cultured
cells must be interpreted with caution. In this study, the cells
were harvested at semi-confluence from media containing
serum. Cell density in culture has been shown to affect
response to exogenous growth factors including TGFP (Ke et
al., 1990) and the relationship of expression of TGFPI1 and
TGF,B2 to cell growth and differentiation in transitional cells
is unknown.
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Table III TGF3Il expression and outcome
Expression
+ +/+ 0
Death from disease 0 1
Progressive diseasea 3 5
Reoccurrenceb 9 3
No reoccurrence 6 0
Death from other causec 4 1
LTFUd 2 2
Total progresseda 3/18 (17%) 6/9 (66%)
aProgression (death from disease or development of disease not
controllable by local resection) P = 0.02 for the association of
reduced expression of TGFP1 (Fisher's test). "Numbers of patients
with tumour re-occurrences are given but this is not considered to be
indicative of disease progression (see text). cOf the five deaths, three
were from unknown causes and two from unrelated conditons.
dLTFU lost to follow up.
Our analysis of tumour and normal urothelial RNA failed
to identify any TGFP2 transcript although the presence and
integrity of RNA of the appropriate size was confirmed. The
level of expression of TGFP1 varied significantly in 50% of
matched field biopsies and tumours. This is perhaps not
surprising as TGFI31 transcription may be auto-regulated
(van Obberghen-Schilling et al., 1988) and suggests that the
use in other studies (e.g. Derynck et al., 1987) of adjacent
non-tumour tissue as a normal control for TGFP1 expression
is inappropriate. We have compared levels of expression in
macroscopically normal biopsies from bladders with and
without tumours at check cystoscopy and from bladders with
no history of transitional cell carcinoma to determine normal
levels of expression. Based on this assessment of normal
TGFP expression, 3/40 tumours showed raised levels and
12/40 showed reduced levels of RNA expression. Transitional
cell carcinomas had previously been resected from all three of
the patients with raised levels of transcript and these patients
all subsequently developed further tumour re-occurrences.
Increased levels of RNA were also found in one unmatched
field control sample and 1 sample of macroscopically normal
urothelium and in one case of follicular cystitis reduced
expression was found. This supported the impression that a
steady state of expression of TGFP1 occurs during relatively
'controlled' growth in urothelium.
The role of TGFPI1 in transformation remains unclear
although the ability of transformed cells to respond to
TGF,B1 is frequently altered (Lechner et al., 1983; McMahon
et al., 1986; Shipley et al., 1986; Wakefield et al., 1987). A
number of studies suggest that altered expression of TGFP1
may play a part in transformation (Derynck et al., 1987;
Jokowlew et al., 1988; Niitsu et al., 1988). Increased levels of
TGFPIB mRNA in tumours compared to adjacent tissues has
been reported in a number of tumours (Derynck et al., 1987),
including breast and renal cell carcinoma (Coombes et al.,
1990; Gomella et al., 1989). It has been suggested that in-
creased expression of TGFP1 by non-responsive tumour cells
may stimulate tumour growth indirectly via paracrine effects
and may also confer an additional advantage on the tumour
by suppressing the hosts immunological surveillance. We
detected raised levels of transcript in only three tumours and
in these there was no obvious correlation with any clinical
parameter.
Reduced levels of TGFPI1 transcript have been reported in
some tumour cell lines (Jakowlew et al., 1988). Undetectable
or reduced levels of TGFPi1 transcript were seen in 12 blad-
der tumours. The significance, if any, of the association
between reduced levels of transcript of TGFPI1 and high
tumour grade is not clear. A larger sample size is required to
clarify this point. However, this was not as striking as the
apparent association of reduced transcript levels with
tumours which in the relatively short period of follow up
became uncontrollable by local means (P<0.02).
A similar reduction in TGFP expression has been reported
in a series of breast tumours analysed by immunohisto-
chemistry, where expression of the TGFP1 gene product was
detected in only 38% (31/82) of tumours and was unrelated
to stage and grade (Mizukami et al., 1990). In these breast
tumours, it was observed that tumours expressing TGFPI1
were associated with a better prognosis over 2 years. Thus, a
reduction in TGFP expression may be common to both
aggressive breast and bladder tumours. A number of other
molecular changes have been described in both tumour types.
These include amplification and overexpression of ERBB2
(Coombs et al., 1989, 1991; Slamon et al., 1987, 1989),
amplification at 1 1q13 involving INT2, HST and BCL1 (Pro-
ctor et al., 1991; Adnane et al., 1989), and loss of
heterozygosity of the RB gene (Cairns et al., 1991; Varley et
al., 1989).
The association of reduced expression of TGFPi1 mRNA
and poor prognosis is in keeping with the known growth
inhibitory activity of TGFP1 on normal epithelial cells. Loss
of expression ofTGFP1 might result in reduction of extracel-
lular matrix formation, increased pericellular proteolysis and
removal of the negative effect on proliferation (Sporn &
Roberts, 1990). Further studies are now required to investi-
gate the relationship of TGFPi1 transcript levels to levels of
the mature active gene product in bladder tumours.
Although only a relatively small number of tumours have
been examined, there appears to be a relationship between
reduced levels of expression of TGFPI1 transcript and disease
progression. From the information obtained in this study, the
presumed loss of the inhibitory activity of TGFP1 in transi-
tional cell carcinoma may be a late event in bladder car-
cinogenesis. However, this does not preclude its utility as a
clinical marker of progression or prognosis.
We are extremely grateful to the Consultant surgeons and their staff
who co-operated in the collection of tissues for this study. We also
thank Dr G. Currie for helpful discussions and Mrs J. Wood for
careful preparation of the manuscript.
References
ADNANE, J., GAUDRAY, P., SIMON, M.-P., SIMONY-LAFONTAINE,
J., JEANTEUR, P. & THEILLET, C. (1989). Protooncogene
amplification and human breast tumour phenotype. Oncogene, 4,
1389-1395.
ASSOIAN, R.K., KOMORIYA, A., MEYERS, C.A., MILLER, D.M. &
SPORN, M.B. (1983). Transforming growth factor 1 in human
platelets. Identification of a major storage site, purification and
characterization. J. Biol. Chem., 258, 7155-7160.
CAIRNS, J.P., PROCTOR, A.J. & KNOWLES, M.A. (1991). Loss of
heterozygosity at the RB locus is frequent and correlates with
muscle invasion in bladder carcinoma. Oncogene, 6,
2305-2309.
CHEIFETZ, S., WEATHERBEE, J.A., TSANG, M.L-S., ANDERSON, J.K.,
MOLE, J.E., LUCAS, R. & MASSAGUE, J. (1987). The transforming
growth factor-P system, a complex pattern of cross reactive
ligands and receptors. Cell, 48, 409-415.
CHEIFETZ, S., HERNANDEZ, H., LAIHO, M., TEN DIJKE, P., IWATA,
K.K. & MASSAGUE, J. (1990). Distinct transforming growth
factor-P (TGF-,B) receptor subsets as determinants of cellular
responsiveness to three TGF-P isoforms. J. Biol. Chem., 265,
20533-20538.
COOMBES, R.C., BARRETT-LEE, P. & LUQMANI, Y. (1990). Growth
factor expression in breast tissue. J. Steriod. Biochem. Mol. Biol.,
37, 833-836.
COOMBS, L.M., KNOWLES, M.A. & MILROY, E.(1989). Her 2 (c-erbB-
2, neu MAC 117) amplification and expression in transitional cell
carcinoma. Urol. Res., 17, 345.
COOMBS, L.M, PIGOTT, D.A., SWEENEY, E., PROCTOR, A.J., EYD-
MANN, M.E., PARKINSON, C. & KNOWLES, M.A. (1991).
Amplification and overexpression of c-erbB-2 in transitional cell
carcinoma of the urinary bladder. Br. J. Cancer, 63, 601-608.TGFPi EXPRESSION IN TCC 583
DERYNCK, R., LINDQUIST, P.B., LEE, A., WEN, D., TAMM, J.,
GRAYCAR, J.L., RHEE, L., MASON, A.J., MILLER, D.A., COFFEY,
R.J., MOSES, H.L. & CHEN, E.Y. (1988). A new type of transform-
ing growth factor-P, TGF-,B3. EMBO J., 7, 3737-3743.
DERYNCK, R., GOEDDEL, D.V., ULLRICH, A., GUTTERMAN, J.U.,
WILLIAMS, R.D., BRINGMAN, T.S. & BERGER, W.H. (1987). Syn-
thesis of messenger RNAs for transforming growth factors ot and
P and the epidermal growth factor receptor by human tumours.
Cancer Res., 47, 707-712.
EVANS, D.R., IRWIN, R.J., HAVRE, P.A., BOUCHARD, J.G., KATO, T.
& PROUT, G.R. (1977). The activity of the pyrimidine biosynthetic
pathway in MGH-U1 transitional carcinoma cells grown in tissue
culture. J. Urol., 117, 712-719.
FEINBERG, A.P. & VOGELSTEIN, B. (1982). A technique for
radiolabelling DNA restriction endonuclease fragments to high
specific activity. Analyt. Biochem., 132, 6-13.
FORT, P., MARTY, L., PIECHACZYK, M., EL SABROUTY, S., DANI,
C., JEANTEUR, P. & BLANCHARD, J.M. (1985). Various rat adult
tissues express only one major mRNA species from the
glyceraldehyde-3-phosphate dehydrogenase multigenic family.
Nucl. Acids Res., 13, 1431-1442.
GOMELLA, L.G., SARGENT, E.R., WADE, T.P., ANGLARD, P.,
LINEHAN, W.M. & KASID, A. (1989). Expression of transforming
growth factor a in normal human adult kidney and enhanced
expression of transforming growth factors a and P1, in renal cell
carcinoma. Cancer Res., 49, 6972-6975.
HITI, A.L., RIDEOUT, W.M. III, LAUG, W.E., & JONES, P.A. (1990).
Plasminogen activator regulation by transforming growth factor-
P in normal and neoplastic human urothelium. Cancer Commun.,
2, 123-128.
IKEDA, T., LIOUBIN, M.N. & MARQUARDT, H. (1987). Human trans-
forming growth factor type P2; production by a prostatic adeno-
carcinoma cell line, purification and initial characterization.
Biochemistry, 26, 2406-2410.
JAKOWLEW, S.B., KONDAIAH, P., FLANDERS, K.C., THOMPSON,
N.C., DILLARD, P.J., SPORN, M.B. & ROBERTS, A.B. (1988). In-
creased coordinate expression of growth factor mRNA accom-
panies viral transformation of rodent cells. Oncogene Res., 2,
135-148.
JETTEN, A.M., SHIRLEY, J.E. & STONER, G. (1986). Regulation of
proliferation and differentiation of respiratory tract epithelial cells
by TGF-,B. Exp. Cell Res., 167, 539-549.
KE, Y., GERWIN, B.L., RUSKIE, S.E., PFEIZER, A.M., HARRIS, C.C. &
LECHNER, J.F. (1990). Cell density governs the ability of human
brochial cells to recognise serum and transforming growth factor-
P1 as squamous differentiation inducing agents. Am. J. Pathol.,
137, 833-843.
KRYCEVE-MARTINERIE, C., LAWRENCE, D.A., CROCKETT, J., JUL-
LIEN, P. & VIGIER, P. (1985). Further study of ,B-TGFs released
by virally transformed and non-tranformed cells. Int. J. Cancer,
35, 553-558.
KUROKOWA, M., LYNCH, K. & PODOLSKY, D.K. (1987). Effects of
growth factors on an intestinal epithelial cell line: TGF-P inhibits
proliferation and stimulates differentiation. Biochem. Biophys.
Res. Commun., 142, 775-782.
KYRIAZIS, A.A., KYRIAZIS, A.P., MCCOMBS, W.B. III. & PETERSON,
W.D.J. (1984). Morphological, biological and biochemical charac-
teristics of human-transitional cell carcinomas grown in tissue
culture and in nude mice. Cancer Res., 44, 3997-4005.
LECHNER, J.F., MCCLENDON, I.A., LAVECK, M.A., SHAMSUDDIN,
A.M. & HARRIS, C.C. (1983). Differential control by platelet fac-
tors of squamous differentiation in normal and malignant bron-
chial epithelial cells. Cancer Res., 43, 5915-5921.
MADISEN, L., WEBB, N.R., ROSE, T.M., MARQUARDT, H., IKEDA, T.,
TWARDZIK, D., SEYEDIN, S. & PURCHIO, A.F. (1988). Trans-
forming growth factor-P2: cDNA cloning and sequence analysis.
DNA, 7, 1 -8.
MANIATIS, T., FRITSCH, E.F. & SAMBROOK, J. (1982). Molecular
Cloning. A Laboratory Manual. Cold Spring Harbor
Laboratory.
MAPSTONE, T., MCMICHAEL, M. & GOLDTHWAIT, D. (1991). Ex-
pression of platelet derived growth factors, transforming growth
factors, and the ras gene in a variety of primary brain tumours.
Neurosurgery, 28, 216-222.
MASUI, T., WAKEFIELD, L.M., LECHNER, J.F., LA VECK, M.A.,
SPORN, M.B. & HARRIS, C.C. (1986). Type 13 transforming growth
factor is the primary differentiation-inducing serum factor for
normal human bronchial epithelial cells. Proc. Natl Acad. Sci.
USA., 83, 2438-2442.
MCMAHON, J.B., RICHARDS, W.L., DEL CAMPO, A.A., SONG, M-K.H.
& THORGEIRSSON, S.S. (1986). Differential effects of transform-
ing growth factor-13 on proliferation of normal and malignant rat
liver epithelial cells in culture. Cancer Res., 46, 4665-4671.
MIZUKAMI, Y., NONOMURA, A., YAMADA, T., KURUMAYA, H.,
HAYASHI, M., KOYASAKI, N., TANIYA, T., NOGUCHI, M.,
NAKAMURA, S. & MATSUBARA, F. (1990). Immunohisto-
chemical demonstration of growth factors, TGF-alpha, TGF-
beta, IGF-1 and NEU oncogene product in benign and malig-
nant human breast tissue. Anticancer Res., 10, 115-126.
MOSES, H.L., TUCKER, R.F., LEOF, E.B., COFFEY, R.J., HALPER, J. &
SHIPLEY, G.D. (1985). Type-P transforming growth factor is a
growth stimulator and growth inhibitor. In: Cancer Cells Vol. 3
Cold Spring Harbor, New York, Feramisco, J., Ozanne, B. &
Stiles, C. (eds) pp. 65-71.
MOSES, H.L., YANG, E.Y. & PIETENPOL, J.A. (1990). TGF-P stimula-
tion and inhibition of cell proliferation: new mechanistic insights.
Cell, 63, 245-247.
NIITSU, Y., URUSHIZAKI, Y., KOSHIDA, Y., TERUI, K., MAHARA,
K., KOHGO, Y. & URUSHIZAKI, I. (1988). Expression of TGF-P
gene in adult T cell leukaemia. Blood, 71, 263-266.
OFFICE OF POPULATION AND CONSENSUSES AND STUDIES,
M.B.I. 1971-1984, Cancer Statistics, H.M.S.O.
O'TOOLE, C., NAYAK, S., PRICE, Z., GILBERT, W.H. & WAISMAN, J.
(1976). A cell line (SCaBER) derived from squamous cell car-
cinoma of the human urinary bladder. Int. J. Cancer., 17,
707-7,
PAULIE, S., HANSSON, Y., LUNDBLAD, M.-L. & PERLMANN, P.
(1983). Lectins as probes for identification of tumor-associated
antigens on urothelial and colonie carcinoma cell lines. Int. J.
Cancer, 31, 297-303.
PROCTOR, A.J., COOMBS, L.,M., CAIRNS, J.P. & KNOWLES, M.A.
(1991). Amplification at chromosome 1 lql3 in transitional cell
tumours of the bladder. Oncogene, 6, 789-795.
PRYOR, J.P. (1973). Factors influencing the survival of patients with
transitional cell tumours of the urinary bladder. Br. J. Urol., 45,
586-592.
ROBERTS, A.B., THOMPSON, N.C., HEINE, U., FLANDERS, C. &
SPORN, M.B. (1988). Transforming growth factor P: possible roles
in carcinogenesis. Br. J. Cancer, 57, 594-600.
ROBERTS, A.B. & SPORN, M.B. (1990). The transforming growth
factor-Ps. In: Peptide Growth Factors and Their Receptors I.
Sporn, M.B., Roberts, A.B. (eds). Springer Verlag, Berlin
Heidleberg, pp. 419-472.
SEYEDIN, S.M., THOMAS, T.C., THOMPSON, A.Y., ROSEN, D.M. &
PIEZ, K.A. (1985). Purification and characterization of two
cartilage-inducing factors from bovine demineralized bone. Proc.
Natl Acad. Sci. USA, 82, 2267-2271.
SHIPLEY, G.D., PITTELKOW, M.R., WILLE, J.J., SCOTT, R.E. &
MOSES, H.L. (1986). Reversible inhibition of normal human pro-
keratinocyte proliferation by type P transforming growth factor-
growth inhibitor in serum-free medium. Cancer Res., 46,
2068-2071.
SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A.
& MCGUIRE, W.L. (1987). Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu
oncogene. Science, 235, 177-182.
SLAMON, D.J., GODOLPHIN, W., JONES, L.A., HOLT, J.A., WONG,
S.G., KEITH, D.E., LEVIN, W.J., STUART, S.G., UDOVE, J.,
ULLRICH, A. & PRESS, M.F. (1989). Studies of the HER-2/neu
protooncogene in human breast and ovarian cancer. Science, 244,
707-712.
SOUTHERN, E.M. (1975). Detection of specific sequences among
DNA fragments separated by gel electrophoresis. J. Mol. Biol.,
98, 503-517.
THOMAS, P.S. (1980). Hybridisation of denatured RNA and small
DNA fragments transferred to introcellulose. Proc. Natl Acad.
Scie. USA, 77, 5201-5205.
UNION INTERNATIONALE CONTRE LE CANCER. (1978). TNM
classification of malignant tumours. Third edition Geneva Inter-
national Union against Cancer. 113-117.
VARLEY, J.M., ARMOUR, J., SWALLOW, J.E., JEFFREYS, A.J.,
PONDER, B.A.J., T'ANG, A., FUNG, Y.-K.T., BRAMMAR, W.J. &
WALKER, R.A. (1989). The retinoblastoma gene is frequently
altered leading to loss of expression in primary breast tumours.
Oncogene, 4, 725-729.
VAN OBBERGHEN-SCHILLING, E., ROCHE, N.S., FLANDERS, K.C.,
SPORN, M.B. & ROBERTS, A.B. (1988). Transforming growth fac-
tor 131 positively regulates its own expression in normal and
transformed cells. J. Biol. Chem., 263, 7741-7746.
WAKEFIELD, L.M., SMITH, D.M., FLANDERS, K.C. & SPORN, M.B.
(1987). Characterisation of a latent form of transforming growth
factor 13 secreted by human platelets. J. Cell Biochem Suppl., 1IIA,
46.584 L.M. COOMBS et al.
WILLIAMS, R.D. (1980). Human urologic cancer cell lines. Invest
Urol., 17, 359-363.
WORLD HEALTH ORGANIZATION (1973). Histological typing of
urinary bladder tumours. In: International Histological
Classification of Tumours No. 10, Geneva.
WRANN, M., BODMER, S., DE MARTIN, R., SIEPL, C., HOFER-
WARBINEK, R., FREI, K., HOFER, E. & FONTANA, A. (1987). T
cell suppressor factor from human glioblastoma cells is a 12.5 kd
protein closely related to transforming growth factor-P. EMBO.
J., 6, 1633-1636.